IL207578A - מעכבים הטרוציטליים של סטרואיל–coa–דסאטוראז, הרכבים רוקחיים המכילים אותם, ושימושם בהכנת תרופות - Google Patents

מעכבים הטרוציטליים של סטרואיל–coa–דסאטוראז, הרכבים רוקחיים המכילים אותם, ושימושם בהכנת תרופות

Info

Publication number
IL207578A
IL207578A IL207578A IL20757810A IL207578A IL 207578 A IL207578 A IL 207578A IL 207578 A IL207578 A IL 207578A IL 20757810 A IL20757810 A IL 20757810A IL 207578 A IL207578 A IL 207578A
Authority
IL
Israel
Prior art keywords
methyl
carboxamide
oxoimidazolidin
thiazole
oxo
Prior art date
Application number
IL207578A
Other languages
English (en)
Other versions
IL207578A0 (en
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL207578(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of IL207578A0 publication Critical patent/IL207578A0/en
Publication of IL207578A publication Critical patent/IL207578A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL207578A 2008-02-20 2010-08-12 מעכבים הטרוציטליים של סטרואיל–coa–דסאטוראז, הרכבים רוקחיים המכילים אותם, ושימושם בהכנת תרופות IL207578A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20
PCT/EP2009/051926 WO2009103739A1 (en) 2008-02-20 2009-02-18 Heterocyclic inhibitors of stearoyl-coa desaturase

Publications (2)

Publication Number Publication Date
IL207578A0 IL207578A0 (en) 2010-12-30
IL207578A true IL207578A (he) 2014-11-30

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207578A IL207578A (he) 2008-02-20 2010-08-12 מעכבים הטרוציטליים של סטרואיל–coa–דסאטוראז, הרכבים רוקחיים המכילים אותם, ושימושם בהכנת תרופות

Country Status (29)

Country Link
US (2) US8049016B2 (he)
EP (1) EP2245029B1 (he)
JP (2) JP5507474B2 (he)
KR (1) KR101584826B1 (he)
CN (1) CN102007123B (he)
AR (1) AR070429A1 (he)
AU (1) AU2009216769A1 (he)
BR (1) BRPI0907826A2 (he)
CA (1) CA2715947C (he)
CL (1) CL2009000381A1 (he)
CO (1) CO6290655A2 (he)
CR (1) CR11629A (he)
CU (1) CU23890B1 (he)
EA (1) EA022797B1 (he)
EC (1) ECSP10010411A (he)
HK (1) HK1144808A1 (he)
HN (1) HN2010001647A (he)
IL (1) IL207578A (he)
JO (1) JO3014B1 (he)
MA (1) MA32150B1 (he)
MX (1) MX2010009158A (he)
MY (1) MY156317A (he)
NZ (1) NZ587350A (he)
PE (1) PE20091473A1 (he)
SV (1) SV2010003650A (he)
TW (1) TWI457338B (he)
UA (1) UA105000C2 (he)
WO (1) WO2009103739A1 (he)
ZA (1) ZA201005725B (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009109147A (ru) 2006-08-15 2010-09-27 Новартис АГ (CH) Органические соединения
WO2008074835A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
BRPI0907826A2 (pt) 2008-02-20 2019-12-10 Novartis Ag inibidores heterocíclicos de estearoil-coa desaturase
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
MX2012003938A (es) * 2009-10-01 2012-08-03 Xenon Pharmaceuticals Inc Derivados de pirazol que modulan la estearoil-coa-desaturasa.
PE20150224A1 (es) * 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
US9173883B2 (en) 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
WO2018045907A1 (zh) * 2016-09-08 2018-03-15 四川科伦博泰生物医药股份有限公司 一种新型2-酰氨基噻唑衍生物及其制备方法与用途
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
IL304017A (he) 2017-01-06 2023-08-01 Yumanity Therapeutics Inc שיטות לטיפול בהפרעות נוירולוגיות
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
CA3127791A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058617A (en) 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
CH590267A5 (he) * 1972-10-04 1977-07-29 Ciba Geigy Ag
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
US20090192191A1 (en) 2004-01-09 2009-07-30 Braj Bhushan Lohray Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
JP4958786B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
WO2006034341A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
WO2007143597A2 (en) 2006-06-05 2007-12-13 Novartis Ag Organic compounds
RU2009109147A (ru) * 2006-08-15 2010-09-27 Новартис АГ (CH) Органические соединения
US8314138B2 (en) 2006-08-24 2012-11-20 Novartis Ag Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes
CA2662574A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
WO2008074835A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
MX2010008818A (es) * 2008-02-13 2010-09-07 Eisai R&D Man Co Ltd Derivado de bicicloamina.
BRPI0907826A2 (pt) 2008-02-20 2019-12-10 Novartis Ag inibidores heterocíclicos de estearoil-coa desaturase
KR20110022089A (ko) 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물

Also Published As

Publication number Publication date
EA022797B1 (ru) 2016-03-31
CA2715947A1 (en) 2009-08-27
NZ587350A (en) 2012-07-27
TWI457338B (zh) 2014-10-21
HN2010001647A (es) 2013-11-11
MA32150B1 (fr) 2011-03-01
AR070429A1 (es) 2010-04-07
IL207578A0 (en) 2010-12-30
CL2009000381A1 (es) 2010-09-10
CO6290655A2 (es) 2011-06-20
CA2715947C (en) 2016-10-25
US8318949B2 (en) 2012-11-27
WO2009103739A1 (en) 2009-08-27
SV2010003650A (es) 2011-07-05
MY156317A (en) 2016-02-15
EP2245029A1 (en) 2010-11-03
JO3014B1 (ar) 2016-09-05
US20090264444A1 (en) 2009-10-22
TW200942534A (en) 2009-10-16
AU2009216769A1 (en) 2009-08-27
US8049016B2 (en) 2011-11-01
EA201001315A1 (ru) 2011-06-30
ECSP10010411A (es) 2010-09-30
CN102007123A (zh) 2011-04-06
JP2014132025A (ja) 2014-07-17
JP5507474B2 (ja) 2014-05-28
BRPI0907826A2 (pt) 2019-12-10
CU23890B1 (es) 2013-04-19
KR101584826B1 (ko) 2016-01-18
CR11629A (es) 2010-11-16
UA105000C2 (uk) 2014-04-10
US20120014906A1 (en) 2012-01-19
MX2010009158A (es) 2010-09-24
CU20100170A7 (es) 2011-10-31
CN102007123B (zh) 2014-04-30
KR20100117677A (ko) 2010-11-03
JP5813162B2 (ja) 2015-11-17
HK1144808A1 (en) 2011-03-11
JP2011512384A (ja) 2011-04-21
EP2245029B1 (en) 2015-04-15
ZA201005725B (en) 2011-04-28
PE20091473A1 (es) 2009-10-23

Similar Documents

Publication Publication Date Title
CA2715947C (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TWI404718B (zh) 調節硬脂醯CoA去飽和酶活性之化合物及其用途
US8258160B2 (en) SCD1 inhibitors triazole and tetrazole compounds
AU2009264242A1 (en) Organic compounds
CA2662574A1 (en) Heterocyclic organic compounds
WO2007143597A2 (en) Organic compounds
CA2776294A1 (en) Pyrazole derivatives which modulate stearoyl-coa desaturase
AU2013200845B2 (en) Heterocyclic inhibitors of stearoyl-CoA desaturase

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees